Skip to main content
Erschienen in: Esophagus 2/2016

25.08.2015 | Original Article

Pulmonary metastasectomy for metachronous metastasis of esophageal cancer after esophagectomy

verfasst von: Motohiro Hirao, Hideyasu Omiya, Koji Takami, Kazuyoshi Yamamoto, Kazuhiro Nishikawa, Masataka Ikeda, Atsushi Miyamoto, Naoki Hama, Masakazu Miyake, Mamoru Uemura, Sakae Maeda, Shoji Nakamori, Mitsugu Sekimoto

Erschienen in: Esophagus | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Background and objective

Pulmonary metastasectomy is a standard therapy for some types of metastatic lesions in the lung. Although the prognosis for esophageal cancer patients with pulmonary metastasis is poor, it has been reported that some post-esophagectomy patients have good prognosis after pulmonary metastasectomy. We investigated the role of resecting pulmonary metastases arising from esophageal cancer at our institution.

Patients and methods

Seven patients with primary squamous cell carcinoma or adenocarcinoma of the thoracic esophagus who underwent resection of metachronous pulmonary metastases at our institution between 2006 and 2012 were identified from a retrospective database. All patients had undergone curative resection of their primary esophageal carcinoma.

Results

Six patients had unilateral and solitary lung metastasis. One patient presented with one metastatic lesion on each side, and he underwent 4 metastasectomy for pulmonary metastasis 3 times. There was no perioperative morbidity or mortality. The disease-free interval after esophagectomy ranged from 191 to 559 days (median, 463 days). Survival after pulmonary metastasectomy ranged from 357 to 3191 days (median, 1803 days). Three patients received systemic chemotherapy before metastasectomy. Currently, 5 patients are alive without evidence of recurrent disease.

Conclusion

Pulmonary metastasectomy may be acceptable as a part of multimodal treatment for solitary metachronous pulmonary metastasis in esophageal carcinoma.
Literatur
1.
Zurück zum Zitat Law SY, Fok M, Wong J. Pattern of recurrence after oesophageal resection for cancer: clinical implications. Br J Surg. 1996;83:107–11.CrossRefPubMed Law SY, Fok M, Wong J. Pattern of recurrence after oesophageal resection for cancer: clinical implications. Br J Surg. 1996;83:107–11.CrossRefPubMed
2.
Zurück zum Zitat Kunisaki C, Makino H, Takagawa R, et al. Surgical outcomes in esophageal cancer patients with tumor recurrence after curative esophagectomy. J Gastrointest Surg. 2008;12:802–10.CrossRefPubMed Kunisaki C, Makino H, Takagawa R, et al. Surgical outcomes in esophageal cancer patients with tumor recurrence after curative esophagectomy. J Gastrointest Surg. 2008;12:802–10.CrossRefPubMed
3.
Zurück zum Zitat Nakagawa S, Kanda T, Kosugi S, et al. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg. 2004;198:205–11.CrossRefPubMed Nakagawa S, Kanda T, Kosugi S, et al. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg. 2004;198:205–11.CrossRefPubMed
4.
Zurück zum Zitat Makowiec F, Baier P, Kulemann B, et al. Improved long-term survival after esophagectomy for esophageal cancer: influence of epidemiologic shift and neoadjuvant therapy. J Gastrointest Surg. 2013;17:1193–201.CrossRefPubMed Makowiec F, Baier P, Kulemann B, et al. Improved long-term survival after esophagectomy for esophageal cancer: influence of epidemiologic shift and neoadjuvant therapy. J Gastrointest Surg. 2013;17:1193–201.CrossRefPubMed
5.
Zurück zum Zitat Blom RL, Lagarde SM, van Oudenaarde K, et al. Survival after recurrent esophageal carcinoma has not improved over the past 18 years. Ann Surg Oncol. 2013;20:2693–8.CrossRefPubMed Blom RL, Lagarde SM, van Oudenaarde K, et al. Survival after recurrent esophageal carcinoma has not improved over the past 18 years. Ann Surg Oncol. 2013;20:2693–8.CrossRefPubMed
6.
Zurück zum Zitat Ichikawa H, Kosugi S, Nakagawa S, et al. Operative treatment for metachronous pulmonary metastasis from esophageal carcinoma. Surgery. 2011;149:164–70.CrossRefPubMed Ichikawa H, Kosugi S, Nakagawa S, et al. Operative treatment for metachronous pulmonary metastasis from esophageal carcinoma. Surgery. 2011;149:164–70.CrossRefPubMed
7.
Zurück zum Zitat Shiono S, Kawamura M, Sato T, et al. Disease-free interval length correlates to prognosis of patients who underwent metastasectomy for esophageal lung metastases. J Thorac Oncol. 2008;3:1046–9.CrossRefPubMed Shiono S, Kawamura M, Sato T, et al. Disease-free interval length correlates to prognosis of patients who underwent metastasectomy for esophageal lung metastases. J Thorac Oncol. 2008;3:1046–9.CrossRefPubMed
8.
Zurück zum Zitat Kozu Y, Sato H, Tsubosa Y, et al. Surgical treatment for pulmonary metastases from esophageal carcinoma after definitive chemoradiation therapy: experience from single institution. J Cardiothorac Surg. 2011;6:135.CrossRefPubMedPubMedCentral Kozu Y, Sato H, Tsubosa Y, et al. Surgical treatment for pulmonary metastases from esophageal carcinoma after definitive chemoradiation therapy: experience from single institution. J Cardiothorac Surg. 2011;6:135.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Chen F, Sato K, Sakai H, et al. Pulmonary resection for metastasis from esophageal carcinoma. Interact Cardiovasc Thorac Surg. 2008;7:809–12.CrossRefPubMed Chen F, Sato K, Sakai H, et al. Pulmonary resection for metastasis from esophageal carcinoma. Interact Cardiovasc Thorac Surg. 2008;7:809–12.CrossRefPubMed
10.
Zurück zum Zitat Takemura M, Sakurai K, Takii M, et al. Metachronous pulmonary metastasis after radical esophagectomy for esophageal cancer: prognosis and outcome. J Cardiothorac Surg. 2012;7:103.CrossRefPubMedPubMedCentral Takemura M, Sakurai K, Takii M, et al. Metachronous pulmonary metastasis after radical esophagectomy for esophageal cancer: prognosis and outcome. J Cardiothorac Surg. 2012;7:103.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Kobayashi N, Kohno T, Haruta S, et al. Pulmonary metastasectomy secondary to esophageal carcinoma: long-term survival and prognostic factors. Ann Surg Oncol. 2014;21:365–9.CrossRef Kobayashi N, Kohno T, Haruta S, et al. Pulmonary metastasectomy secondary to esophageal carcinoma: long-term survival and prognostic factors. Ann Surg Oncol. 2014;21:365–9.CrossRef
12.
Zurück zum Zitat Thomford NR, Woolner LB, Clagett OT. The surgical treatment of metastatic tumors in the lungs. J Thorac Cardiovasc Surg. 1965;49:357–63.PubMed Thomford NR, Woolner LB, Clagett OT. The surgical treatment of metastatic tumors in the lungs. J Thorac Cardiovasc Surg. 1965;49:357–63.PubMed
13.
Zurück zum Zitat Japanese Society for Esophageal Diseases. Guideline for clinical and pathological studies on carcinoma of the esophagus. 9th ed. Esophagus, 2004;1:61–88, 2004;1:108–25. Japanese Society for Esophageal Diseases. Guideline for clinical and pathological studies on carcinoma of the esophagus. 9th ed. Esophagus, 2004;1:61–88, 2004;1:108–25.
14.
Zurück zum Zitat Morita M, Yoshida R, Ikeda K, et al. Advances in esophageal cancer surgery in Japan: analysis of 1000 consecutive patients treated at a single institution. Surgery. 2008;143:499–508.CrossRefPubMed Morita M, Yoshida R, Ikeda K, et al. Advances in esophageal cancer surgery in Japan: analysis of 1000 consecutive patients treated at a single institution. Surgery. 2008;143:499–508.CrossRefPubMed
15.
Zurück zum Zitat Bhansali M, Fujita H, Kakegawa T, et al. Pattern of recurrence after extended radical esophagectomy with three- field lymph node dissection for squamous cell carcinoma in the thoracic esophagus. World J Surg. 1997;21:275–81.CrossRefPubMed Bhansali M, Fujita H, Kakegawa T, et al. Pattern of recurrence after extended radical esophagectomy with three- field lymph node dissection for squamous cell carcinoma in the thoracic esophagus. World J Surg. 1997;21:275–81.CrossRefPubMed
16.
Zurück zum Zitat Osugi H, Takemura M, Higashino M, et al. Causes of death and pattern of recurrence after esophagectomy and extended lymphadenectomy for squamous cell carcinoma of the thoracic esophagus. Oncol Rep. 2003;10:81–7.PubMed Osugi H, Takemura M, Higashino M, et al. Causes of death and pattern of recurrence after esophagectomy and extended lymphadenectomy for squamous cell carcinoma of the thoracic esophagus. Oncol Rep. 2003;10:81–7.PubMed
Metadaten
Titel
Pulmonary metastasectomy for metachronous metastasis of esophageal cancer after esophagectomy
verfasst von
Motohiro Hirao
Hideyasu Omiya
Koji Takami
Kazuyoshi Yamamoto
Kazuhiro Nishikawa
Masataka Ikeda
Atsushi Miyamoto
Naoki Hama
Masakazu Miyake
Mamoru Uemura
Sakae Maeda
Shoji Nakamori
Mitsugu Sekimoto
Publikationsdatum
25.08.2015
Verlag
Springer Japan
Erschienen in
Esophagus / Ausgabe 2/2016
Print ISSN: 1612-9059
Elektronische ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-015-0506-4

Weitere Artikel der Ausgabe 2/2016

Esophagus 2/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.